Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 14/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.49 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | AKT2 | P31751 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4864372 | 0.78 | GAA (0.53) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL15849494 | 0.74 | TGFBR1 (0.62) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL4863284 | 0.72 | KDM4E (0.64) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL3240693 | 0.72 | TGFBR1 (0.59) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL4030943 | 0.70 | TGFBR1 (0.57) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL4035678 | 0.69 | TGFBR1 (0.56) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL15640139 | 0.69 | TGFBR1 (0.56) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL4033819 | 0.69 | TGFBR1 (0.59) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL8816383 | 0.69 | TGFBR1 (0.66) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL4032898 | 0.68 | TGFBR1 (0.55) | TGFBR1MAPK14RIPK2ACVR1BTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275235-A1 | NOVEL FUSED HETEROAROMATIC COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER INC. (US) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275235-A1 | NOVEL FUSED HETEROAROMATIC COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | TGFBR1, SMAD3, SMAD2 | TGFBR1 1/4885MAPK14 1127/4885RIPK2 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.